Medication vs. Natural

Are Sleeping Pills Safe? What the Research Actually Shows

The answer depends on the drug, the dose, the duration, and who's taking it — but the research paints a more complicated picture than most prescribers discuss.

By Eleanor Hayes, Sleep Health Writer·January 29, 2025·9 min read·Reviewed by Dr. Sarah Chen, MD, Board-Certified Sleep Medicine

Are Sleeping Pills Safe? What the Research Actually Shows — Photograph for Sleep Editorial.

Tens of millions of Americans take sleeping pills on any given night. Zolpidem (Ambien) alone has been one of the most prescribed drugs in the United States for decades. And yet the question of whether sleeping pills are actually safe — not just for an occasional rough night, but as used in the real world — rarely gets the careful answer it deserves. The honest answer is: it depends. It depends on which medication, at what dose, for how long, and in whom. And for several of the most commonly prescribed options, the research paints a significantly more complicated picture than a quick office visit typically conveys.

Key Takeaways

Sleeping pills vary dramatically in their safety profiles — orexin antagonists and melatonin agonists carry lower dependence risk than benzodiazepines and z-drugs
Z-drugs (Ambien, Lunesta, Sonata) carry an FDA black box warning for complex sleep behaviors including sleepwalking and sleep-driving, issued in 2019
Tolerance to most sedative-hypnotics develops within 2–4 weeks, meaning long-term prescriptions deliver diminishing benefit with accumulating risk
OTC antihistamines like diphenhydramine lose effectiveness within 3–4 days and carry anticholinergic effects that are particularly problematic in older adults
CBT-I, not medication, is the first-line recommended treatment for chronic insomnia — with superior long-term outcomes and no dependence risk

The five categories of sleeping pills

To answer the safety question meaningfully, you need to know what kind of sleeping pill you're talking about. The term "sleeping pill" covers at least five distinct drug classes, each working through a different mechanism and carrying a different risk profile.

Z-drugs (non-benzodiazepine sedative-hypnotics)

Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are the most commonly prescribed sleep medications in the United States. Marketed as safer alternatives to benzodiazepines when introduced in the 1990s, z-drugs work by selectively targeting certain subtypes of the GABA-A receptor — the brain's primary inhibitory receptor complex — to produce sedation. In clinical trials, they reliably reduce sleep onset latency and increase total sleep time in the short term.

The safety concerns with z-drugs are now well-documented. Tolerance develops within two to four weeks of regular use, requiring dose escalation to maintain the same effect. Rebound insomnia upon discontinuation — often worse than the original complaint — makes stopping difficult. Dependence, while less severe than with benzodiazepines, is a recognized clinical phenomenon. And in 2019, the FDA issued a black box warning — its most serious — for all three z-drugs, citing reports of complex sleep behaviors including sleepwalking, sleep-driving, preparing and eating food, and having conversations, all while the patient was not fully awake. Some of these behaviors resulted in deaths and serious injuries. The black box warning specifically recommends avoiding z-drugs in patients who have had previous complex sleep behavior episodes.

Benzodiazepines

Temazepam, triazolam, and flurazepam are the benzodiazepines most commonly used for insomnia, though the class has largely been supplanted by z-drugs for sleep indications. Benzodiazepines bind broadly to GABA-A receptors, producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. Their sleep efficacy is real but comes at a significant cost: higher dependence risk than z-drugs, more pronounced cognitive effects, significant withdrawal syndrome with prolonged use, and a particularly unfavorable profile in older adults due to falls risk, cognitive impairment, and the prolonged half-life of some agents like flurazepam.

Orexin receptor antagonists

Suvorexant (Belsomra) and lemborexant (Dayvigo) represent a newer and mechanistically different approach. Rather than forcing sleep by enhancing inhibitory signaling, they block the orexin (hypocretin) system — the brain's primary wake-promoting circuit. When orexin is blocked, the wake drive is reduced rather than the sleep threshold being lowered. This mechanism produces sleep that is closer to physiologically normal, with lower abuse potential and no significant withdrawal syndrome. That said, orexin antagonists are not without risks: next-day impairment — including residual sedation, driving impairment, and cognitive slowing — is documented, particularly at higher doses.

Melatonin agonists

Ramelteon (Rozerem) acts on melatonin receptors in the suprachiasmatic nucleus, the brain's circadian pacemaker, to facilitate sleep onset by signaling darkness. It is not a sedative in the traditional sense — it does not produce the generalized CNS depression of GABA-acting drugs. Dependence risk is minimal, and there is no abuse potential. The tradeoff is modest efficacy: ramelteon reduces sleep onset latency by roughly 10–15 minutes in clinical trials and has minimal effect on sleep maintenance insomnia.

OTC antihistamines

Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs) and doxylamine (Unisom SleepMelts) are the active ingredients in most over-the-counter sleep aids. They produce sedation as a side effect of histamine H1 receptor blockade — the same mechanism that makes antihistamines cause drowsiness. Tolerance develops within three to four days of regular use, essentially eliminating their sleep benefit rapidly. More concerning are anticholinergic effects — dry mouth, constipation, urinary retention, and, in older adults, confusion and cognitive impairment — that emerge even with short-term use and are cumulative over time.

The GABA mechanism and what neuroadaptation means for safety

Understanding why z-drugs and benzodiazepines become less safe over time requires understanding the GABA mechanism. GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. Sedative-hypnotics that enhance GABA activity work by binding to the GABA-A receptor complex and increasing the frequency or duration of chloride channel opening, hyperpolarizing neurons and reducing their firing rate. The result is generalized CNS suppression — sedation, anxiolysis, reduced arousal.

The brain is not a passive target. With repeated enhancement of GABA signaling, the brain undergoes neuroadaptation: GABA-A receptor expression and sensitivity are downregulated, and compensatory upregulation of glutamate — the primary excitatory neurotransmitter — occurs. The result is tolerance: the same dose produces less effect. This is the pharmacological basis for the common clinical experience of sleeping pills "stopping working." It also explains the withdrawal syndrome and rebound insomnia that occur when the drug is removed: the brain, now adapted to operate under pharmacological GABA enhancement, is hyperexcitable when that enhancement is removed.

What "short-term use" actually means

"Short-term use" is a phrase that appears in almost every prescription guideline for sleep medications — but the definition varies. Regulatory approvals for most z-drugs are based on short-term trials of two to four weeks. Clinical guidelines generally recommend use of no more than two to four weeks for z-drugs and benzodiazepines. In practice, studies consistently show that a substantial portion of patients prescribed these medications use them for months or years. The gap between the evidence base (short-term trials) and clinical reality (long-term prescriptions) is where the most serious risks accumulate.

"The evidence base for sleeping pills is almost entirely short-term," says Dr. Thomas Osei of Northwestern Sleep Medicine. "Most trials are two to four weeks. We don't have rigorous long-term safety data for the populations who are actually taking these drugs, which are often older adults with multiple comorbidities using them for years. The risk-benefit calculation changes significantly over time."

When sleeping pills may be appropriate — and when they're not

None of this means sleeping pills are never appropriate. For situational insomnia — a bereavement, a major stressor, jet lag, a medical procedure — short-term use of a well-chosen agent in an otherwise healthy adult carries a very different risk profile than years of nightly use in a 70-year-old with cognitive concerns. Orexin antagonists, with their more favorable dependence and cognitive profiles, represent a meaningfully lower-risk option when medication is genuinely necessary. And for patients who have already been using sleep medication long-term, the path forward is not abrupt cessation but a supervised taper combined with CBT-I — the behavioral treatment that addresses the underlying mechanism.

The broader clinical context is that CBT-I is now the first-line recommendation from every major sleep medicine society — the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society — precisely because it produces durable improvements without the risks that accumulate with pharmacological treatment. Programs like Sleep Reset ($297/month, HSA/FSA eligible) make CBT-I accessible without waitlists or the cost of in-person therapy, delivering the full evidence-based protocol with human coaching.

Frequently Asked Questions

Are sleeping pills safe for long-term use?

The research does not support long-term use of most sleeping pills. Z-drugs and benzodiazepines were approved and tested in short-term trials (2–4 weeks), and the risks — tolerance, dependence, cognitive effects, and in older adults, falls and possible dementia association — accumulate over time. Orexin antagonists have a more favorable profile for extended use, but the evidence base remains limited. Long-term use of any sedative-hypnotic should be regularly reassessed with your prescriber.

What is the FDA black box warning on sleeping pills about?

In 2019, the FDA issued its most serious warning — a black box warning — for zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata), citing serious injuries and deaths from complex sleep behaviors. These behaviors include sleepwalking, sleep-driving, preparing and eating food, and making phone calls while not fully awake. The warning recommends that patients who have experienced any complex sleep behavior on these medications stop taking them immediately and consult their prescriber.

Which sleeping pill is the safest?

Safety depends on the patient and context. Among prescription options, orexin antagonists (suvorexant, lemborexant) and the melatonin agonist ramelteon have the lowest dependence risk and most favorable cognitive profiles. Among OTC options, none have a favorable long-term profile — antihistamines lose effectiveness within days and carry anticholinergic concerns. For chronic insomnia, CBT-I consistently outperforms all medication options in long-term durability without any dependence risk.

Can sleeping pills cause memory loss?

Yes. Anterograde amnesia — the inability to form new memories after taking the medication — is a documented effect of z-drugs and benzodiazepines. This is distinct from the long-term dementia association that has been studied in long-term benzodiazepine users. The acute amnesia effect is dose-dependent and is why some people taking zolpidem wake up with no memory of nighttime activities. The FDA explicitly notes anterograde amnesia as a risk of z-drugs.

Is there a non-medication treatment for insomnia that actually works?

CBT-I (Cognitive Behavioral Therapy for Insomnia) is the most effective treatment for chronic insomnia — more effective than medication at one year and beyond, according to multiple meta-analyses. It is the first-line recommendation from major sleep medicine societies. Sleep Reset delivers the full CBT-I protocol with a dedicated human coach at $297/month, with HSA/FSA eligibility, making it accessible without the cost or wait times of in-person therapy.

Moving Forward

The research landscape on this topic has matured to the point where clear, evidence-based recommendations are available — and where the gap between what the evidence shows and what most people actually receive as treatment remains an important public health problem. Understanding the research, seeking the appropriate treatment for your specific situation, and following through with the behavioral work that evidence-based protocols require are the three steps most likely to produce lasting improvement. The evidence is clear; the access is increasingly available; the work, for those who commit to it, produces results that medication alone cannot match over time.

For anyone still in the early stages of understanding their sleep problem — not yet sure whether what they have is clinical insomnia, a physiological disorder, a circadian issue, or simply inadequate sleep opportunity — the most productive next step is a two-week sleep diary and a conversation with a physician who can review it in clinical context. From that foundation, the appropriate next intervention becomes considerably clearer.

A Non-Pharmacological Path That Outperforms Medication Long-Term

For anyone looking to avoid starting — or to stop using — sleep medication, Sleep Reset is a digital CBT-I program that addresses the behavioral and cognitive factors maintaining insomnia directly. Research shows CBT-I produces durable improvements at one-year follow-up that no sleep medication matches after discontinuation. Sleep Reset's coaching model improves adherence through the early weeks of the protocol when self-directed behavioral change is hardest to sustain.

Disclosure

Sleep Editorial is an independent publication. Expert quotes were obtained through independent reporting. Sleep Editorial does not provide medical advice; consult a qualified clinician before starting, stopping, or modifying any medication or treatment program.